Showing results (241-250 of 349) with videos related to

Sort By:
Pageof 35
Circulation|February 1, 1983
Hemodynamic and neuroendocrine responses to acute and chronic alpha-adrenergic blockade with prazosin and phenoxybenzamineJ Mulvihill-Wilson, F A Gaffney, W A Pettinger, et al.
Thrombosis Research|November 15, 2002
A neoantigenic determinant in the D-dimer fragment of fibrinE V Lugovskoy, I N Kolesnikova, P G Gritsenko, et al.
The American Journal of Cardiology|October 1, 1985
Cardiovascular deconditioning produced by 20 hours of bedrest with head-down tilt (-5 degrees) in middle-aged healthy menF A Gaffney, J V Nixon, E S Karlsson, et al.
Biomechanics and Modeling in Mechanobiology|July 17, 2013
Cellular blebs: pressure-driven, axisymmetric, membrane protrusionsThomas E Woolley, Eamonn A Gaffney, James M Oliver, et al.
Pediatrics|March 5, 2002
A pediatric, practice-based, randomized trial of drinking and smoking prevention and bicycle helmet, gun, and seatbelt safety promotionMarguerite M Stevens, Ardis L Olson, Cecelia A Gaffney, et al.
Controlled Clinical Trials|December 1, 1994
The Nambour Skin Cancer and Actinic Eye Disease Prevention Trial: design and baseline characteristics of participantsA Green, D Battistutta, V Hart, et al.
Public Health Nutrition|November 26, 2011
Is dieting behaviour decreasing in young adolescents?Claire R Whittle, John W G Yarnell, Mike Stevenson, et al.
Mathematical Biosciences|December 21, 2010
A mathematical model of tumour and blood pHe regulation: The HCO3-/CO2 buffering systemNatasha K Martin, Eamonn A Gaffney, Robert A Gatenby, et al.
Molecular Pharmaceutics|May 9, 2018
Theoretical Insights into the Retinal Dynamics of Vascular Endothelial Growth Factor in Patients Treated with Ranibizumab, Based on an Ocular Pharmacokinetic/Pharmacodynamic ModelLaurence A Hutton-Smith, Eamonn A Gaffney, Helen M Byrne, et al.
Molecular Pharmaceutics|January 5, 2016
A Mechanistic Model of the Intravitreal Pharmacokinetics of Large Molecules and the Pharmacodynamic Suppression of Ocular Vascular Endothelial Growth Factor Levels by Ranibizumab in Patients with Neovascular Age-Related Macular DegenerationLaurence A Hutton-Smith, Eamonn A Gaffney, Helen M Byrne, et al.
Pageof 35